

# BOND-003 TRIAL

# DOCTOR DISCUSSION GUIDE

## Non-Muscle Invasive Bladder Cancer

### STUDY DETAILS:

Clinicaltrials.gov ID: NCT04452591

The BOND-003 study is testing an investigational drug called cretostimogene grenadenorepvec (CG0070) for adults with non-muscle invasive bladder cancer (NMIBC) who have already tried BCG treatment. CG0070 is a type of immunotherapy, which is different from chemotherapy. Immunotherapy is a type of cancer treatment that helps your immune system fight cancer.

In this study, CG0070 will be given intravesically, meaning it is put directly into the bladder using a catheter (a thin tube put into your bladder). Throughout the study doctors will monitor your health and how your cancer is responding to the treatment.

### QUESTIONS TO HELP GUIDE CONVERSATIONS WITH YOUR HEALTHCARE PROFESSIONAL:

- Do I meet the requirements to join this study?
- What will my responsibilities be if I participate?
- What are the possible benefits and risks of participating in this clinical trial?
- Who will oversee my medical care?
- What support/resources does the study team offer to participants and caregivers?
- Can I stop participating in the study after it has begun?

If you would like to learn more about the eligibility requirements of this study, please contact us at:

[Recruitment@cgoncology.com](mailto:Recruitment@cgoncology.com)

